/
/
/

Piramal Pharma Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-7%8%-3%
----458%
--29%5%
3%0%-1%-4%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
PPLPHARMA
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,860.2₹447476 Cr3712.0762.82₹11479 Cr
9,614.5₹254764 Cr87.134.04128.41₹2568 Cr
4,957.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,179.1₹116658 Cr25.859.4262.53₹5040 Cr
1,401₹111484 Cr33.089.7757.87₹3879 Cr
2,047.6₹109943 Cr100.556.829.25₹889 Cr
2,496.3₹101712 Cr49.7913.7571.08₹1913 Cr
1,205.8₹101005 Cr31.355.3263.99₹4196 Cr
1,733.1₹99253 Cr26.7317.9596.84₹3505 Cr
2,107.6₹96031 Cr17.3730.95154.35₹5333 Cr
210.09₹28045 Cr-0.524.09-₹326 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
₹1327 Cr₹1324 Cr₹1323 Cr₹1193 Cr₹1186 Cr₹995 Cr
₹73 Cr₹62 Cr₹27 Cr₹0₹0₹10 L
₹6763 Cr₹6739 Cr₹6561 Cr₹5580 Cr₹5511 Cr₹4610 Cr
₹6763 Cr₹6739 Cr₹6561 Cr₹5580 Cr₹5511 Cr₹4610 Cr
₹8163 Cr₹8125 Cr₹7911 Cr₹6774 Cr₹6697 Cr₹5605 Cr
₹4300 Cr₹3214 Cr₹2484 Cr₹3384 Cr₹2622 Cr₹2339 Cr
-₹157 Cr-₹145 Cr-₹157 Cr-₹130 Cr-₹105 Cr-₹22 Cr
₹292 Cr₹275 Cr₹286 Cr₹282 Cr₹240 Cr₹236 Cr
₹94 Cr₹49 Cr₹32 Cr₹276 Cr₹145 Cr₹7 Cr
₹4529 Cr₹3393 Cr₹2645 Cr₹3812 Cr₹2903 Cr₹2560 Cr
₹2479 Cr₹1534 Cr₹1538 Cr₹1193 Cr₹1026 Cr₹918 Cr
₹1479 Cr₹1185 Cr₹1576 Cr₹1305 Cr₹1243 Cr₹1141 Cr
₹748 Cr₹995 Cr₹1171 Cr₹1302 Cr₹659 Cr₹361 Cr
₹169 Cr₹137 Cr₹84 Cr₹51 Cr₹190 Cr₹172 Cr
₹4875 Cr₹3851 Cr₹4369 Cr₹3851 Cr₹3118 Cr₹2591 Cr
₹17567 Cr₹15369 Cr₹14925 Cr₹14437 Cr₹12717 Cr₹10756 Cr
₹96 Cr₹100 Cr₹61 Cr₹57 Cr₹45 Cr₹30 Cr
₹5495 Cr₹4720 Cr₹4559 Cr₹5505 Cr₹4023 Cr₹2910 Cr
₹14905 Cr₹13118 Cr₹12138 Cr₹10842 Cr₹9510 Cr₹8173 Cr
₹6214 Cr₹4984 Cr₹4148 Cr₹3374 Cr₹2631 Cr₹2068 Cr
₹7 Cr₹0₹0₹0₹0₹0
₹8684 Cr₹8133 Cr₹7990 Cr₹7469 Cr₹6879 Cr₹6105 Cr
₹799 Cr₹489 Cr₹566 Cr₹853 Cr₹673 Cr₹400 Cr
₹305 Cr₹271 Cr₹240 Cr₹212 Cr₹217 Cr₹123 Cr
₹305 Cr₹271 Cr₹240 Cr₹212 Cr₹217 Cr₹123 Cr
₹155 Cr₹91 Cr₹115 Cr₹494 Cr₹297 Cr₹152 Cr
₹15 Cr₹15 Cr₹0₹4 L₹4 L₹4 L
₹10259 Cr₹9487 Cr₹9461 Cr₹9593 Cr₹8565 Cr₹7007 Cr
₹132 Cr₹20 Cr₹145 Cr₹427 Cr₹50 Cr₹0
₹3064 Cr₹2313 Cr₹2176 Cr₹1681 Cr₹1389 Cr₹1232 Cr
₹2158 Cr₹2350 Cr₹2134 Cr₹1799 Cr₹1785 Cr₹1575 Cr
₹1224 Cr₹501 Cr₹483 Cr₹308 Cr₹329 Cr₹406 Cr
₹145 Cr₹135 Cr₹82 Cr₹140 Cr₹94 Cr₹141 Cr
₹586 Cr₹563 Cr₹445 Cr₹488 Cr₹505 Cr₹396 Cr
₹7308 Cr₹5881 Cr₹5464 Cr₹4843 Cr₹4152 Cr₹3749 Cr
₹2433 Cr₹2031 Cr₹1095 Cr₹992 Cr₹1034 Cr₹1158 Cr
₹17567 Cr₹15369 Cr₹14925 Cr₹14437 Cr₹12717 Cr₹10756 Cr
₹61₹61₹60₹57₹56₹56
₹61₹61₹60₹55₹55₹55

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
-₹233 Cr₹342 Cr₹120 Cr-₹161 Cr₹441 Cr₹884 Cr
₹1569 Cr₹1373 Cr₹1276 Cr₹1136 Cr₹787 Cr₹478 Cr
₹527 Cr-₹488 Cr-₹234 Cr-₹302 Cr-₹292 Cr-₹620 Cr
₹1863 Cr₹1227 Cr₹1161 Cr₹673 Cr₹936 Cr₹742 Cr
₹1653 Cr₹892 Cr₹1005 Cr₹484 Cr₹766 Cr₹598 Cr
-₹826 Cr-₹477 Cr-₹434 Cr-₹1339 Cr-₹1812 Cr-₹4480 Cr
-₹39 Cr-₹441 Cr-₹422 Cr₹818 Cr₹794 Cr₹3977 Cr
₹788 Cr-₹26 Cr₹148 Cr-₹37 Cr-₹251 Cr₹94 Cr
₹182 Cr₹219 Cr₹53 Cr₹85 Cr₹262 Cr₹152 Cr
₹0₹0₹0₹0₹77 Cr₹0
₹0₹0₹0₹0₹0₹11 Cr
₹6 Cr-₹11 Cr₹18 Cr₹5 Cr-₹2 Cr₹4 Cr
₹976 Cr₹182 Cr₹219 Cr₹53 Cr₹85 Cr₹262 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)210.65
Volume (₹)43.74 L
High (₹)214.89
Upper Circuit252.88
Low (₹)207.10
Lower Circuit168.60
Prev Close210.74
52W High (₹)231.93
Price208.12
52W Low (₹)132.30

Share Market Cap & Key Ratios Overview

M.Cap (₹)28044.80 Cr
Div. Yield (%)0.00
PE Ratio0.00
Debt to Equity0.68
Price to Book2.24
Book Value60.96
EPS (TTM)-2.36
Face Value10.00
ROE (%)-4.04

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
PPLPHARMANSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
208.12-0.04 (-0.02%)
207.10
216.70
28,045Cr

Piramal Pharma Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹284.61Cr; with other income of ₹89.41Cr, profit before interest and tax came to ₹61.06Cr. Interest expense was ₹88.08Cr; PBT before exceptional items stood at ₹-₹27.02Cr. Cost mix (full year): raw materials ₹3426.38Cr; employee cost ₹2415.92Cr; depreciation ₹223.55Cr; other expenses ₹2074.72Cr. Basis: consolidated annual results.

Piramal Pharma Ltd Quaterly Results Key Takeaways

Piramal Pharma Ltd reported ₹2269.92Cr total income from operations in Jun 2026, softer than ₹2751.77Cr in Mar 2026 but higher than ₹1933.71Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹284.61Cr; with other income of ₹89.41Cr, profit before interest and tax came to ₹61.06Cr. Interest expense was ₹88.08Cr, taking profit before tax to ₹-₹27.02Cr. After tax of ₹61.93Cr, profit after tax stood at ₹-₹88.95Cr (vs ₹-₹22.4Cr in Mar 2026 and ₹-₹100.27Cr in Jun 2025).